Gastric cancer (GC) is a high-incidence cancer worldwide. Most patients are diagnosed at an advanced stage, by which time they have limited treatment options and poor prognosis. Early diagnosis and precise treatment are important. In the past few years, emerging research has been conducted on the use of non-invasive liquid biopsy, with its advantages of minimal invasiveness and repeated sampling, to monitor tumor occurrence and recurrence in real time and to evaluate prognosis and treatment response. Many studies have demonstrated the potential of liquid biopsy in GC, and the detection of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating free DNA (cfDNA), and exosomes has achieved gratifying results. In this review, we summarize evolving technologies for and information regarding liquid biopsy, the most recently discovered GC liquid biopsy biomarkers, and ongoing clinical trials and discuss the challenges and application prospects of liquid biopsy in GC.

**INTRODUCTION**

Gastric cancer (GC) is one of the most common cancers and represents the third leading cause of cancer death worldwide, and more than one million patients are diagnosed with GC globally each year [1]. Currently, the primary therapy for GC patients is surgery and systemic chemotherapy; in addition, radiotherapy, immunotherapy, and targeted therapy are gradually being used [2], but the 5-year survival rate of GC patients is still unsatisfactory. Therefore, early detection of GC plays a vital role in the treatment and prognosis of GC [3]. The diagnosis of GC is mainly based on imaging and pathological biopsy [4]. However, imaging cannot be used for real-time monitoring of tumors and exposes patients to radiation, and pathological biopsy is an invasive test that causes discomfort for patients. In contrast, liquid biopsy is being increasingly recognized as a tool for GC diagnosis, treatment, and real-time monitoring [5] (Fig. 1). To a certain extent, liquid biopsy, as a non-invasive detection method, can replace traditional invasive physical biopsy. Despite its many advantages, there are also certain limitations and difficulties in its analysis. Therefore, a new technique with high sensitivity is necessary for people with GC who are at high risk of adverse outcomes.

In recent years, several articles have provided a detailed summary of the role of liquid biopsy in several cancers, such as hepatocellular carcinoma (HCC) [6], pancreatic cancer [7], non-small cell lung cancer [8] and melanoma [9], which has caused an increase in liquid biopsy research in the field of cancer. However, in the field of GC, the research progress of liquid biopsy is relatively slow, and no review articles of sufficient quality have

**FACTS**

1. Liquid biopsies, including circulating tumor cells, circulating tumor DNA, and exosomal RNAs, are novel targets for cancer diagnosis, prognosis, and therapy monitoring.
2. Liquid biopsies achieve higher sensitivity and specificity in cancer diagnosis and prognosis by detecting surface biomarkers, DNA methylation, and chromosomal abbreviation.
3. Clinical trials on liquid biopsy for gastric cancer have been carried out, and progress has been made.

**OPEN QUESTIONS**

1. What is the clinical standard for applying liquid biopsies to gastric cancer patients?
2. What are the most efficient targets for gastric cancer diagnosis, prognosis, and therapy monitoring?
3. Will there be new testing techniques and targets to make liquid biopsy more convenient, economical, and accurate?
been published. Although the study of liquid biopsy related to GC is still in the early stages, the quantity and quality of related research have increased recently. In this review, we mainly emphasize the major advancements in the use of liquid biopsy for early detection, prognostication, and therapy response monitoring in GC.

COMPONENTS AND APPLICATIONS OF LIQUID BIOPSY

Circulating tumor cells (CTCs)

Generally, CTCs are cells that are shed from primary tumor foci into the peripheral circulation or invade blood vessels through epithelial–mesenchymal transition [10] (Fig. 2). Thus, CTCs have drawn much attention as valuable diagnostic, prognostic, and even treatment response and resistance biomarkers for various cancers [11]. These cells hold valuable information (Fig. 1). The application of CTCs as prognostic biomarkers has received considerable attention in multiple tumors. First, the number of CTCs is measured. It has been reported that CTCs can be used to predict the survival rate and monitor recurrence after surgery. For example, Pierga et al. showed that breast cancer patients with more than one CTC per 7.5 ml of blood had shorter progression-free survival (PFS) \( (p < 0.0001) \), and those with more than five CTCs per 7.5 ml of blood had shorter overall survival (OS) \( [12] \). In addition to the quantitation of CTCs, chromosome rearrangements in CTCs can be detected by fluorescence in situ hybridization (FISH), genetic changes in CTCs can be detected by genome sequencing, and CTC protein expression can be detected by immunocytochemistry \( [13] \). Based on the characteristics of CTCs, clinicians can select the most appropriate treatment, and therapy response can be reflected in changes in CTCs. In colorectal cancer (CRC), molecular analysis of single CTCs revealed significant intra-patient and inter-patient heterogeneity in mutant EGFR expression as well as that of other genetic mutations relating to EGFR inhibition, such as KRAS and PIK3CA mutations, which explains the diverse response rates to EGFR-targeted therapy in patients with CRC \( [14] \). For patients with castration-resistant prostate cancer, the number of posttreatment CTCs was revealed to be an earlier biomarker to evaluate the effectiveness of treatment than prostate specific antigen (PSA) \( [15] \). Moreover, enriched CTCs can be cultured ex vivo, enabling personalized therapy to be determined based on genetic profiling and novel drug sensitivity testing on ex vivo CTCs \( [16] \). More clinical studies and advanced CTC detection and collection techniques need to be developed to realize the transition of CTC applications from bench to bedside.

GC diagnosis through CTCs and cell surface biomarkers. Owing to the malignancy and late diagnosis of GC, early detection of GC is of great value to achieve successful treatment for patients. Only a few studies have focused on applying CTCs as a diagnostic marker for GC; however, the outcomes have been quite surprising (Table 1). According to Yoon-Kyung Cho, 7.5 ml of blood was collected from 115 GC patients and 31 healthy controls, and CTCs were separated via a centrifugal microfluidic system. A total of 97.1% of subjects with more than two CTCs were GC patients, representing a specificity of 90.3%. Nevertheless, 38% of GC patients had less than two CTCs per 7.5 ml, indicating that the sensitivity of this method needs to be improved \( [17] \). According to a previous study, a GC stem cell biomarker, CD44, was specifically expressed in GC patients compared to healthy controls. Thus, diagnosing GC based on enriched CTCs can be cultured ex vivo, enabling personalized therapy to be determined based on genetic profiling and novel drug sensitivity testing on ex vivo CTCs \( [16] \). More clinical studies and advanced CTC detection and collection techniques need to be developed to realize the transition of CTC applications from bench to bedside.

![Flowchart of applying liquid biopsy in GC](image)

**Fig. 1** Flowchart of applying liquid biopsy in GC. Blood, saliva, urine, and gastric juice are collected and targets of liquid biopsies, such as CTCs, ctDNA/cfDNA or exosome RNAs, were enriched to achieve early detection, prognosis, and monitoring therapy responses.
molecule (EpCAM). Nevertheless, more research needs to be done to examine the efficiency of PTK7 and EpCAM in blood samples [19]. In addition, according to Huang et al., CTCs are significantly related to clinicopathological features, such as the differentiation and stage, of tumors [20]. Generally, CTCs are detected by EpCAM on cell surface. However, in GC, some of CTCs with highly invasive and metastatic capacity do not express EpCAM on cell surface. RUBYchip™, a recently developed CTCs isolation technique, recognizes CTCs according to cell size and deformability, greatly improving CTCs capture rates [21].

Predicting GC patients’ prognosis through CTCs. Many studies suggest that CTCs are among the most important prognostic biomarkers for many cancers. Significant correlations between CTC counts and patient survival time have been found in many studies. CTCs were strongly related to poor overall survival (OS) in patients with GC, according to the findings of seven investigations involving 579 patients with GC from four countries [22]. However, the standard number of CTCs used as a cut-off varies in different studies. For example, a study of 72 patients found that patients with more than one CTC in blood had shorter disease-free survival (DFS), \((p = 0.001)\) and OS \((p = 0.0007)\) than patients without CTCs [23]. In contrast, GC patients with more than five CTCs in 7.5 mL of peripheral blood had a worse relapse-free survival (RFS) than those with less than five CTCs [24]. In addition, it was reported that CTCs tended to aggregate, forming circulating tumor microemboli (CTM), which would facilitate cancer metastasis. The more CTCs aggregated, the worse OS would be. The OS of GC patients with CTM2 (made of 2 CTCs) was almost 10 months longer than that of GC patients with CTM3-4 (made of 3-4 CTCs) [25]. Further studies demonstrated that CTCs expressing specific molecules are potential biomarkers for GC patient prognosis. For instance, N-cadherin is a marker related to GC relapse, and patients can be characterized as having different risks of recurrence according to the number of N-cadherin+ CTCs [26]. Likewise, GC patients with more carcinoembryonic antigen positive (CEA) cells were highly likely to experience relapse within three years [27]. CD44+ cells were commonly detected in the blood or bone marrow of patients with distant metastasis, and their detection was associated with shorter OS [28]. CD133 and ABCG2 are biomarkers of cancer stem cells. GC patients with upregulated CD133+ and ABCG2+ CTCs were found to have shorter OS [29]. In addition, GC patients with more than 2.5 TWIST+ CTCs per 7.5 ml of blood had shorter OS than patients with fewer than 2.5 TWIST+ CTCs [30]. Moreover, Qiu et al. found that CTCs associated with white blood cell clusters (CTC-WBC clusters) were more sensitive markers to predict prognosis for gastric cancer patients. Patients with CTC-WBC clusters had shorter OS than those without CTC-WBC clusters [31]. Moreover, also genomic alterations in CTCs seem to have prognostic value. In particular, the presence of 2 CTCs with aneuploidy of chromosome 8 per 7.5 mL in GC patients correlated with shorter OS and PFS [32]. In conclusion, CTCs are a meaningful target in GC prognosis and thus deserve further research.

Predicting therapy response via CTCs. CTC-positive (CTC+) patients experience shorter PFS and a lower disease control rate (DCR) after therapy than CTC-negative patients [22]. However, the definition of CTC+ still needs to be clarified. According to a

---

**Fig. 2** Components of liquid biopsy in GC. CTCs, ctDNA, and exosomes were discovered in the peripheral blood. CTCs and ctDNA are important ingredients that are usually regarded as the foundations of liquid biopsy. ctDNA is formed from apoptotic and necrotic tumor cells, which release fragmented DNA into the bloodstream and possess genetic aberration from original tumor cells. CTCs are cancer cells that spontaneously shed from primary or metastatic tumors and circulate in the circulation. They are tumor “seeds” and can result in recurrence by hepatic metastasis, lymphatic metastasis, and angiogenesis.
Another study indicated that after 6 weeks of chemotherapy, the presence of more than 4 CTCs had fewer CTCs [34]. Nonetheless, other studies showed that the shorter PFS in patients with more than four CTCs than in those who had fewer CTCs [34]. Nonetheless, other studies showed that the presence of more than five CTCs in the blood is an appropriate cut-off value for predicting therapy response. Patients with five CTCs or more were highly likely to experience progressive disease (PD) and shorter PFS [35]. Moreover, CTCs can be divided into epithelial type, expressing keratins 8, 18, and 19 and EpCAM, and mesenchymal type, expressing vimentin and TWIST, in GC patients. Increased mesenchymal-type CTCs after chemotherapy indicated that patients were overwhelmingly likely to experience PD [36].

**Table 1. Liquid biopsy of CTCs and ctDNA/cfDNA in GC.**

| Clinical scenario | Liquid biopsy strategy | Study | Target | Patients | Sensitivity | Specificity | AUC |
|-------------------|-----------------------|-------|--------|----------|-------------|------------|-----|
| Early detection   | CTC detection         | [53]  | Detection of ≥ 2 CTCs/7.5 ml blood | 116 GC, 31 healthy | 85.3% | 90.3% | |
|                   | CTC marker            | [54]  | CD44   | 26 GC, 12 healthy | 92.3% | 100% | 0.9744 |
|                   | cfDNA                 | [58]  | Detection of cfDNA ≥ 90 ng/ml | 30 GC, 34 healthy | 96.67% | 94.11% | 0.991 |
|                   | ctDNA methylation     | [60]  | Differentially methylated regions (DMR) | 300 GI tumor | / | / | 0.90 |
|                   | ctDNA methylation     | [62–65] | XAF1, PCDH10, RASSF1A, RUNX3, RPRML | | | |

**Prognosis**

| Study | Detection of ≥ 2 CTCs/7.5 ml blood | Association with overall survival and disease-free survival |
|-------|-----------------------------------|---------------------------------------------------------|
| CTC detection | [73] | Detection of ≥ 5 CTCs/7.5 ml blood | Association with relapse free survival |
| CTC detection | [74] | The number of CTCs after surgery | Association with recurrence and relapse free survival |
| CTC marker | [77] | CEA, EpCAM | Association with shorter three-year relapse free survival |
| CTC marker | [78] | CD44 | Association with shorter overall survival |
| CTC marker | [79] | CD133 | Association with shorter overall survival |
| CTC marker | [80] | TWIST | TWIST (+) CTCs ≥ 2.5/7.5 mL of blood tended have shorter overall survival |
| Multiploid CTC | [81] | Aneuploidy of chromosome 8 | Association with shorter progression-free survival and overall survival |
| ctDNA detection | [84] | Detection of ctDNA after surgery | Association with shorter disease-free survival and overall survival |
| ctDNA detection | [87] | Detection of ctDNA after surgery | Association with shorter relapse-free survival and overall survival |
| cfDNA genetic alteration | [88] | Genetic alteration derived from GC | Association with shorter overall survival |
| ctDNA genetic alteration | [89] | BRAF/FGFR2 amplification and ARAF mutation | Association with shorter overall survival |
| ctDNA genetic alteration | [90] | TP53 mutation and MET amplification | Association with shorter overall survival |
| ctDNA methylation | [92] | Methylated TIMP-3 | Association with shorter disease-free survival and overall survival |

**Circulating tumor DNA (ctDNA)/cell-free DNA (cfDNA)**

In the bloodstream, cfDNA is DNA fragments released by cells, and ctDNA is composed of (ctDNA, circulating cell-free mitochondrial DNA, and cell-free fetal DNA. ctDNA refers to DNA fragments originating from cancer cells [42]. Studies have confirmed that ctDNA can be secreted from primary tumor cells, metastatic tumor cells and CTCs and actively or passively released by tumor cells by Mishima et al., an advanced technique named 3D-IF-FISH has higher sensitivity for detecting HER2+ CTCs than traditional tissue biopsy, and patients with HER2+ detected via CTCA analysis but HER2- detected via tissue biopsy were benefi
cial from trastuzumab therapy [38]. According to Matsushita et al., HER2+ CTCs are an independent prognostic marker for GC patients related to favorable OS and PFS, regardless of histological HER2 status [39]. Furthermore, the number of HER2+ CTCs was reduced after trastuzumab therapy, while it rebounded when drug resistance developed. Therefore, the number of HER2+ CTCs is a useful tool for monitoring the effectiveness of trastuzumab therapy [40]. Innate resistance to trastuzumab can result from PIK3CA mutation, and acquired resistance can be caused by mutation of PIK3R1 or PIK3C3 or mutation of HER2. Hence, it is not surprising that HER2+ CTC patients had short PFS and benefitted little from trastuzumab therapy [41].
undergoing apoptosis or necrosis [43]. In healthy individuals, cfDNA is nearly absent. In cases of malignant tumors, chronic inflammation, and excessive cell death, cfDNA will substantially accumulate. Allele-specific polymerase chain reaction, amplification at lower denaturation temperatures (COLD), emulsion PCR, and massively parallel sequencing are among the technologies being developed for cfDNA analysis [44]. cfDNA has been detected in many types of cancer. Owing to its origin, cfDNA contains all the genetic features, such as the mutations, amplifications, deletions, and/or translocations, that primary and metastatic tumor cells have. Studies have shown that the analysis of cfDNA and/or ctDNA is a more sensitive method for identifying tumor-specific genetic changes than traditional biopsies or the assessment of normal cancer biomarkers used in the clinic. For instance, the detection rate of FGFR2 amplification was higher with ctDNA analysis than with tissue biopsy because of tumor heterogeneity, which improves the treatment efficiency [45].

Assessing the methylated cfDNA profile through liquid biopsy significantly improves early diagnosis efficiency. To distinguish methylated ctDNA from a large amount of cfDNA derived from normal tissue, Shen et al. developed cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), which is able to detect methylated cfDNA in only 1–10 ng of DNA. One of the advantages of cfMeDIP-seq is that different types of samples can be used, for example, urine and cerebrospinal fluid [46]. Nuzzo et al. validated the sensitivity of cfMeDIP-seq as a method to diagnose early-stage renal cell carcinoma via patient blood or urine [47]. Currently, the use of non-invasive liquid biopsies to obtain methylated cfDNA has drawn substantial research attention, and studies have been performed on different cancers. For instance, by comparing HCC tissue and normal blood leukocytes, an HCC-specific methylation marker panel was discovered by Xu et al. After validation in cfDNA from a large clinical cohort, ten HCC-specific methylation markers were selected to construct a diagnostic prediction model with high diagnostic specificity (94.3%) and sensitivity (85.7%) [48]. In 2020, a single ctDNA methylation marker, cg10673833, was discovered for diagnosing CRC and showed 86.8% specificity and 89.7% sensitivity [49].

**GC diagnosis through ctDNA/cfDNA methylation profile.** Notably, cfDNA increases as GC progresses. Diagnosing GC through cfDNA achieved 96.67% sensitivity and 94.11% specificity when the cfDNA threshold was 90 ng/ml [50]. Zhong et al. revealed that the diagnostic value of cfDNA was higher than that of traditional biomarkers, such as CA199, CA125, and AFP, as demonstrated by receiver operating characteristic (ROC) analysis [51]. As mentioned above, methylated cfDNA and ctDNA are important research topics. Recently, genome-wide methylation analysis was performed based on the methylation information of 1781 gastro-intestinal stromal (GI) tumors and adjacent normal tissues, which was subsequently validated by 300 cfDNA. The results showed that GI cancers could be distinguished by differentially methylated regions obtained from blood samples [52]. Furthermore, a 153 cfDNA methylation biomarker panel including DOCK10, CABIN1, and KCNQ5 was identified in a GC patient cohort, providing a novel method to diagnose early-stage gastric cancer [53]. XAF1 was found to be downregulated in GC patients because of a high percentage of methylation in cancer tissues (83.2%) compared to paracancerous histologically normal tissues (27.2%) and healthy controls (0%). Consistent with the pathological results, a high frequency of XAF1 methylation was detected in cfDNA of GC patients (69.8%, 141 of 202), and no methylation was detected in cfDNA of 88 healthy controls [54]. Furthermore, studies found elevated methylated tumor suppressor genes in cfDNA, including PCDH10, RASSF1A, RUNX3, and RPRM, specifically in blood samples from GC patients, which produced satisfactory sensitivity and specificity, suggesting that methylation of these genes has the potential to be a diagnostic biomarker [55–57]. Moreover, methylated cfDNA and ctDNA can predict the clinicopathological characteristics of tumors. In several studies, GC patients with lymphatic metastasis, distant metastasis, and advanced TNM stage generally had higher levels of SFRP2 [58], APC [59], and SOX17 [60] methylation in ctDNA. Ling et al. found that the levels of abnormally methylated MINT2 and THBS1 in cfDNA were positively correlated with peritoneal dissemination and tumor progression [61, 62].

**Predicting GC patient prognosis via ctDNA/cfDNA mutation and methylation profile.** Owing to the short half-life of ctDNA/cfDNA, they are capable of reflecting tumor status in an almost real-time manner, making them potential prognostic biomarkers for GC patients [63]. Relapse occurred in every GC patient who had detectable ctDNA after surgery, and shorter disease free survival (DFS) and OS were observed in these patients [64]. In addition, GC patients with a high level of long fragment cell-free DNA after curative surgery showed worse DFS and OS [65]. Thirty-five GC patients had single-nucleotide variants and copy number alterations in serum ctDNA in a cohort of forty GC patients, confirming that a high proportion (87.5%) of patients had genomic alterations [66]. The cfDNA level was 44 times higher in GC patients than in healthy controls, while the DNA fragment length became shorter as the scale expanded. cfDNA retains somatic mutations derived from GC tissue and is positively correlated with worse survival time [67]. A study by Catenacci et al. demonstrated that most GC patients (77%) have at least one genomic alteration. The results showed that amplification of BRAF/FGFR2 and mutation of ARAF indicated worse survival [68]. Furthermore, a study suggested that GC patients with TP53 mutation or MET amplification had shorter overall survival than those without these alterations [69]. It is worth mentioning that methylation of cfDNA or ctDNA not only aids the timely detection of GC but is also quickly becoming a key tool for predicting patient outcomes; for example, methylation of PCDH10, RASSF1A, XAF1, SOX17, and WIF-I in cfDNA or ctDNA has shown potential [54, 55, 70]. Generally, hypermethylation of these genes indicates unfavorable outcomes, such as relapse, poor response to therapy, and worse survival time. TIMP-3 methylation was upregulated in GC tissue and was found to be strongly associated with peritoneal metastasis and TNM stage. Approxi-
mately half of the GC patients were found to have methylated TIMP-3 in preoperative peritoneal washes and serum samples. Patients with higher methylation levels of TIMP-3 in their body fluids had shorter DFS [71]. It is easy to conclude that the scale and genetic or epigenetic changes of ctDNA/cfDNA are important parameters to predict the prognosis of GC patients.

**ctDNA/cfDNA predicting therapy efficiency.** The amount of cfDNA or ctDNA after therapy predicts the outcomes of patients suffering from different tumors [72]. After treatment, GC patients with PD had higher concentrations of plasma cfDNA/cfDNA over time; for patients with partial response, the concentration of ctDNA/cfDNA increased; cfDNA/cfDNA remained stable in stable disease patients [51, 72]. PD-L1 therapy is approved as primary immunotherapy to treat metastatic GC, but its efficacy in patients varies. The mutational load of cancer, which can be somewhat reflected by ctDNA, was found to be significantly associated with the response to PD-L1 therapy, specifically pembrolizumab. Patients with a higher mutational load in ctDNA before treatment achieved an ORR of 83.3%, while those with a low mutational load achieved an ORR of only 7.7%. Research also found that patients with reduced ctDNA six weeks after therapy had extended PFS [73]. Thus, ctDNA could be regarded as a response and PFS predictor for GC patients. In addition, chromosomal accessibility of circulating CD8+ T cells is a potential PD-1 blockade therapy predictor for GC patients. Shin et al. showed that the openness of the chromatin structure in circulating CD8+ T cells is associated with a good
response to anti-PD-1 therapies and a long survival time in GC patients [74]. Chromosomal instability, represented by copy number instability (CNI) in ctDNA, was negatively correlated with the efficacy of treatment. CNI decreased in patients who were sensitive to treatment, while it increased in patients who were resistant to therapy [75]. In conclusion, it is highly valuable to detect mutations and scales of ctDNA before, after, or during treatment in order to evaluate the efficiency of treatments.

cDNA/cfDNA predicting therapy resistance. A study found that patients with mutations in TGFBR2, RHOA, and PREX2 were resistant to PD-1 antibody therapy, and these patients had significantly shorter PFS than those who did not. In addition, the results showed that newly generated mutations in FOXL2 and RHOA and copy number variations of FGFR2 were responsible for acquired resistance to immunotherapy in patients who previously had good responses to PD-1 antibody therapy [76]. Synchronous MET amplification limits the efficacy of FGFR2 inhibitors for FGFR2-amplified GC patients [45]. MET-amplified oesophagogastric cancer with newly generated KRAS mutations and HER2 amplification resisted MET inhibitor therapy [77]. HER2 + cfDNA indicated a good response rate to therapy. However, cooccurring CCNE1 amplification in cfDNA was associated with HER2-targeted therapy resistance, while newly emerged HER2 amplification increased sensitivity to HER2-targeted therapy [78]. Genomic alterations caused by therapy are thought to play a pivotal role in chemotherapy resistance. On the other hand, genomic alterations that are already present in the tumor before the start of any treatment could be the determinant of response to therapy.

Exosomes and noncoding RNAs

Exosomes have drawn much attention in scientific research in the past ten years, and our team also reviewed the role and application of small extracellular vesicles (EVs) in GC [79]. Exosomes are small (30–140 nm) membrane-bound EVs that are secreted by large multivesicular bodies and are released into the extracellular environment through fusion; in addition, they can be detected in blood, urine, cerebrospinal fluid, and other body fluids. Many cell types can release exosomes, such as epithelial cells, haematopoietic cells, neuronal cells, fibroblasts, adipocytes, and tumor cells. Notably, exosomes regulate and participate in physiological and pathological processes [80]. Studies have shown that noncoding RNAs, for example, microRNAs (miRNAs), circular RNAs (circRNAs), and long noncoding RNAs (lncRNAs), which are normally easily degraded, can be packaged into exosomes, which allows them to remain stable in the extracellular environment and transmit signals between cells and tissues. Many academic studies have elucidated that exosomal RNAs are related to epithelial–mesenchymal transition, angiogenesis, the formation of the premetastatic niche, metastasis, the immune response, and therapeutic resistance, indicating that exosomal RNAs play an important role in the initiation and progression of cancer [81]. In 2008, Li et al. demonstrated that the expression of mir-21 was elevated in patients suffering from breast cancer. Furthermore, breast cancer patients with higher levels of mir-21 tended to have an advanced clinical stage, lymph node metastasis and shorter OS than patients with lower levels of mir-21. Therefore, mir-21 is regarded as a potential prognostic biomarker for breast cancer. Because of the ease with which they can be collected, exosomes and exosomal RNAs have significant advantages as biomarkers in non-invasive liquid biopsies [82]. Sun et al. established a tumor immune infiltration-associated IncRNA signature composed of seven lncRNAs through computational immune and IncRNA profiling analysis based on data from non-small cell lung cancer cell lines and patients. These seven lncRNAs could be used to divide patients into immune hot and immune cold groups. The results revealed that patients in the immune hot group generally had upregulation of immune checkpoint gene expression, which led to longer OS and a good response to immune checkpoint inhibitor therapy, indicating its potential in monitoring therapy response [83].

GC diagnosis through exosomal noncoding RNA. In recent years, a considerable amount of literature related to the use of exosomes and exosomal RNAs as diagnostic biomarkers for GC has appeared. In general, in these studies, blood samples were collected from both GC patients and healthy controls, and the level of exosomal RNAs was measured via quantitative reverse transcription PCR. Exosomal RNAs with significant expression differences between GC patients and healthy controls are regarded as candidate exosomal RNAs. Then, the sensitivity, specificity, and area under the ROC curve (AUC) values of these candidate exosomal RNAs were calculated. Those exosomal RNAs with favorable values are reported as potential diagnostic biomarkers. Some studies use a combination of miRNAs to increase the efficiency of diagnosis. For instance, a circRNA panel was identified by Roy et al. based on a cohort of 194 GC patients. This panel achieved the diagnosis of GC patients from healthy controls with high sensitivity and specificity in both the validation and training phases. Furthermore, this circRNA panel was capable of distinguishing early-stage GC from healthy controls, as well as the histological type of GC [84]. In addition, an onco-miRNA panel consisting of exosomal mir-10a-5p, mir-19b-3p, mir-215-5p, and mir-18a-5p was also identified [85]. Detailed information on diagnostic exosomal RNAs is presented in Table 2 below.

GC prognosis through exosomal noncoding RNAs. Many studies to determine the prognostic value of exosomal RNAs are underway. Most of these studies focus on the correlation between exosomal RNAs and survival time. Unfortunately, only a few studies have investigated the mechanism behind the correlation. For instance, Fan et al. revealed that there was a close relationship between exosomal PD-L1 and worse OS in GC patients. The reason for the unfavorable outcomes was that exosomal PD-L1 exerted suppressive effects on the immune status of GC patients by reducing the number of CD4+ T cells, CD8+ T cells, and granzyyme B+ cells [86]. Details of exosomal RNAs as prognostic biomarkers are shown in Table 3.

Tumor-educated platelets

Tumor-educated platelets (TEPs) are one of the newest liquid biopsy components. On the one hand, TEPs help cancer cells grow and escape from the immune system. Platelets exhibiting particular RNA fingerprints from cancer cells are said to have been educated by cancer [87]. As reported by Calverley et al., 197 platelet genes were downregulated in patients with metastatic lung cancer [88]. Moreover, not only platelet genes but also cancer-related genes were expressed in TEPs. Nilsson et al. found that cancer-specific EGFR and PCA3 RNAs were expressed in platelets of glioma and prostate cancer patients [89]. Therefore, TEPs have received considerable attention for their impressive diagnostic value in cancer. In 2015, pan-cancer research on TEPs was performed by Best et al. In terms of mRNA profiles, there were significant differences between TEPs and normal controls in multiple tumor types, and these profiles had 89% accuracy in cancer diagnosis [90].

Other resources

The most important source of specimens in liquid biopsy is blood. Blood-based biopsy technologies were the earliest to be developed because they can be widely used in clinics and cause relatively little damage to patients. Studies suggest that body fluids other than the blood can also be critical sources for liquid biopsies [91]. For instance, bladder cancer patients could be distinguished from healthy controls by detecting the frequency of FGFR3 mutations in urine [92]. Head and neck squamous cell...
cancers can be diagnosed by detecting tumor DNA in saliva [93]. Tumor mutations can be found in the cerebrospinal fluid cfDNA of individuals with various primary or metastatic brain cancers [94]. In terms of GC, more studies exploring the application of body fluids other than blood in GC are needed. Nerve growth factors released by GC cells throughout development stimulate salivary glands, resulting in significant changes in the saliva RNA profile that can be utilized to detect GC [95]. Concerning salivary extracellular RNA, a panel comprising three mRNAs and two miRNAs was established and showed high feasibility in diagnosing GC; the panel was also validated in a cohort of 294 individuals [96]. Gastric juice and washes have the closest relationship with GC and are essential resources for liquid biopsies. The differential expression of certain miRNAs and lncRNAs (including miR-21, miR-106a, and IncRNA-AA174084) in gastric juice has the potential to diagnose GC [97–99]. DNA methylation was detected in gastric washes, and GC patients and normal controls showed significant differences in methylation profiles. The sensitivity and specificity reached 90% and 96%, respectively, when diagnosing GC via MINT methylation profiles [100]. Substances secreted by GC cells enter the blood first and are ultimately excreted into the urine through the kidneys. In urine samples, miR-6807-5p, miR-6856-5p, and miR-23-5p were found to be initially highly expressed and reduced after surgery in GC patients, which made them potential biomarkers for early detection and monitoring therapy response [101, 102]. In addition, upregulation of the serum antibody BRAT1 was found to be useful in achieving early detection of gastrointestinal cancers [103].

APPLICATIONS OF AND PERSPECTIVES ON LIQUID BIOPSY IN GC

Clinical trials of liquid biopsy in GC

The clinical trials of GC-related liquid biopsy are relatively extensive, as it is a common area of interest for clinicians (Table 4). As listed in the table, the purpose of most liquid biopsies

| Table 2. Exosomal RNAs in diagnosis of GC. |
|--------------------------------------------|
| Biomarker | Type     | Expression | Sensitivity/specificity | Correlation           | AUC      |
| miR-1290  | microRNA | up         | 26%/90%                | TNM stage, distant metastasis | 0.657    |
| miR-25    | microRNA | up         | 69.4%/84.6%            | TNM stage, LNM        | 0.768    |
| miR-222   | microRNA | up         | 62.5%/56.2%            |                       | 0.747    |
| miR-196a  | microRNA | up         | 69.5%/97.6            |                       | 0.864    |
| miR-196b  | microRNA | up         | 62.2%/96.1%            |                       | 0.811    |
| miR-26a   | microRNA | down       | 83.6%/81.5%            |                       | 0.882    |
| miR146-3p | microRNA | down       | 74.4%/84.1%            |                       | 0.839    |
| miR-148a  | microRNA | down       | 75.4%/83.1%            |                       | 0.842    |
| miR-195   | microRNA | down       | 69.2%/75.4%            |                       | 0.765    |
| miR-106a  | microRNA | up         | 72.9%/63.6%            | TNM stage, LNM       | 0.828    |
| miR-21    | microRNA | up         | 88.4%/79.6%            |                       | 0.912    |
| miR-421   | microRNA | up         | 90%/85.7%              |                       | 0.779    |
| miR-199a-3p | microRNA | up     | 76%/74%               |                       | 0.818    |
| miR-200c  | microRNA | up         | 65.4%/100%             |                       | 0.715    |
| miR-212   | microRNA | down       | 95.1%/78.7%            |                       | 0.960    |
| miR-1, 20a, 27a, 34, 423-5p | microRNA | up     | 80%/81%               | TNM stage            | 0.879    |
| miR-19a-3p, 483-5p | microRNA | up     | 87.7%/62.8%           |                       | 0.84     |
| miR-627, 629, 652 | microRNA | up     | 86.7%/85.5%           |                       | 0.941    |
| hsa_circ_0000190 | circRNA | down   | 41.4%/97.5%           | TNM stage, LNM       | 0.60     |
| hsa_circ_0130810 | circRNA | down   | 77.4%/68%             | TNM stage, LNM       | 0.748    |
| hsa_circ_0021977 | circRNA | down   | 85.8%/92.4%           | TNM stage            | 0.933    |
| hsa_circ_0006848 | circRNA | down   | 73.3%/90%             | TNM stage, tumor differentiation | 0.825 |
| hsa_circ_0001821 | circRNA | down   | 86.67%/86.67%         | TNM stage, LNM       | 0.872    |
| hsa_circ_0065149 | circRNA | down   | 48.7%/90.2%           | TNM stage            | 0.640    |
| FRLnc1     | IncRNA   | up         | 74.5%/76.8%            | TNM stage, LNM       | 0.709    |
| RP11-731F5.2 | IncRNA   | up         | 81.6%/63.64%          |                       | 0.78     |
| IncRNA-GC1 | IncRNA   | up         | 87.21%/87.10%         | clinical stage       | 0.886    |
| CEBPA-AS1  | IncRNA   | up         | 87.9%/78.8%            | TNM stage            | 0.824    |
| PCGEM1     | IncRNA   | up         | 72.9%/88.9%            | TNM stage, tumor differentiation | 0.75     |
| HOXA11-AS  | IncRNA   | up         | 78.7%/97.8%            | TNM stage, LNM       | 0.924    |
| IncUEGC1   | IncRNA   | up         | 88.24%/83.33%         | TNM stage            | 0.876    |
| HOTTIP     | IncRNA   | up         | 69.8%/85.0%            | TNM stage            | 0.827    |
| PVT1       | IncRNA   | up         | 80.2%/60.4%            | TNM stage, LNM       | 0.728    |
| HULC       | IncRNA   | up         | 82%/83.6%              | TNM stage            | 0.888    |
| H19        | IncRNA   | up         | 82.9%/72.9%            |                       | 0.838    |
| UCA1       | IncRNA   | up         |                       |                      | 0.883    |
is to predict prognosis and evaluate therapeutic efficiency. Three other trials are aimed at achieving an early diagnosis of GC through liquid biopsies. For example, cfMeDIP-Seq assay is used to not only screen cancer patients from healthy people but also to distinguish cancer types. Tumor-derived mutations, for instance, mutations of \(CDH1\) and \(CTNNA1\) which are commonly detected in hereditary diffuse GC, are detected by next-generation sequencing. To achieve prognosis prediction, the majority of clinical trials are designed to detect ctDNA or CTCs before and after GC treatment in a scheduled interval to evaluate the correlation with OS, DFS PFS, and RFS. Concerning therapeutic evaluation, a trial for HER2 positive GC was launched by scholars from China, intending to evaluate the HER2 targeted therapy by monitoring HER2 status in CTCs, HER2 amplifications in cfDNA, and therapy resistance-related gene status in both CTCs and cfDNA from before treatment to disease remission or progression. In recent years, immunotherapy research has achieved impressive results in many tumors, including GC. To select GC patients suited for immunotherapy, several clinical trials have evaluated the efficacy of immunotherapy via liquid biopsy. *FoundationOneLiquid*, applied by PLATON, provides information like microsatellite instability (MSI) and tumor mutational burden to help inform immunotherapy decisions. Moreover, for MSI-high gastric/gastroesophageal junction cancer, whether to use tremelimumab and durvalumab as neoadjuvant or definitive treatment is evaluated by clinical trial INFINITY. Another clinical trial, named INTEGA, compared the efficacy between chemotherapy-free immunotherapy and immunotherapy after FOLFOX chemotherapy for HER2+ gastric/gastroesophageal junction cancer patients. Results showed that early cfDNA increases strongly correlated to shorter PFS and OS. Besides, trastuzumab resistance is due to HER2 mutation and epitope scape, resulting in trastuzumab resistance loss. In

| Table 3. Exosomal RNAs in prognostic evaluation of GC. |
|----------------|----------------|----------------|
| Biomarker      | Type           | Expression     | Correlation   |
| miR-25         | microRNA       | up             | OS, RFS      |
| miR-212        | microRNA       | down           | OS           |
| miR-144        | microRNA       | down           | OS, DFS      |
| miR-215-5p     | microRNA       | up             | OS           |
| miR-3178       | microRNA       | down           | OS           |
| miR-21-3p      | microRNA       | up             | OS, PFS      |
| miR-324-5p     | microRNA       | up             | OS           |
| miR-203        | microRNA       | down           | OS, DFS      |
| hsa_circ_0021977 | circRNA     | down           | OS           |
| hsa_circ_0000936 | circRNA     | up             | OS           |
| hsa_circ_405576  | circRNA      | up             | OS, RFS      |
| hsa_circ_0065149 | circRNA     | down           | OS           |
| RP11-731F5.2   | IncRNA         | up             | OS           |
| HOXA11-AS      | IncRNA         | up             | OS           |
| HOTTIP         | IncRNA         | up             | OS           |
| PVT1           | IncRNA         | up             | OS, DFS      |

| Table 4. Liquid biopsy in clinical trials of GC. |
|----------------|----------------|----------------|----------------|
| Identifier     | Disease                  | Intervention                                      | Purpose                                      | Country     |
| NCT04253106    | Hereditary Diffuse Gastric Cancer | plasma and gastric fluid genetic profiles | Diagnosis | France |
| NCT04943406    | Gastric Cancer/Gastric Adenocarcinoma | plasma and peritoneal lavage ctDNA | Prognosis | Italy |
| NCT05029869    | Gastric Cancer           | plasma ctDNA                                     | Prognosis | Vietnam |
| NCT03957564    | Gastric Cancer/Gastro-esophageal Junction Cancer | plasma CTC, ctDNA and cfDNA | Prognosis and response to neoadjuvant chemotherapy | China |
| NCT04385316    | Gastric Cancer           | plasma ctDNA                                     | Diagnosis | China |
| NCT02610218    | Advanced/Metastatic Gastric Cancer | plasma CTC and cfDNA | Prognosis and response to targeted therapy | China |
| NCT04665687    | Early Gastric Cancer     | plasma ctDNA                                     | Prognosis and diagnosis                     | Korea |
| NCT05027347    | Early Gastric Cancer     | plasma ctDNA                                     | Prognosis                                   | Vietnam |
| NCT04000425    | Gastric Cancer           | plasma ctDNA                                     | Prognosis and response to adjuvant chemotherapy | China |
| NCT04817826    | Gastric Cancer           | plasma ctDNA                                     | Prognosis and response to neoadjuvant immunotherapy | Italy |
| NCT04484636    | Gastric Cancer           | plasma ctDNA                                     | Response to immunotherapy                  | Germany |
| NCT03409848    | Gastric Cancer           | plasma ctDNA                                     | Response to immunotherapy                  | Germany |
addition, scholars are evaluating the probability of other body fluids, like gastric juice and peritoneal lavage, being potential liquid biopsy samples for GC.

**Challenges and perspectives of liquid biopsy in GC**

Liquid biopsies, especially ctDNA and CTCs testing, have drawn a lot of attention. Minimally invasive sampling, dynamic monitoring, and a comprehensive understanding of cancer are its main advantages. Furthermore, there is sufficient research to suggest that liquid biopsy for early-stage and advanced cancers has implications for clinical decision-making, especially when tissue biopsy is suboptimal or inaccessible. Thus, we performed a search of articles published on the Web of Science in the past five years and visualized the evidence-based results through bibliometric methods. We used “gastric cancer” and “liquid biopsy” as keywords to draw the network and time series diagrams to analyze the development trends in this field (Fig. 3). The application of liquid biopsies shifts from diagnosis and prognosis to treatment management, such as chemotherapy and immunotherapy. The sample changes from blood plasma to other body fluids, such as urine, cerebrospinal fluid, gastric juice, and saliva. The targets develop from protein tumor markers to circulating tumor cells or DNA(CTC/ctDNA) to circulating tumor RNA, exosomal RNA, and tumor-educated platelets. The analysis method shifts from quantification to genomic or epigenomic analysis to in vitro or in vivo experiments (Fig. 4). However, the development and progression of liquid biopsy in GC is relatively slow compared to other cancer, such as lung cancer, colorectal cancer, and hepatocellular cancer. Therefore, liquid biopsy in GC has great potential for making further progress.

In terms of early GC diagnosis, common tumor-driver gene mutations in cfDNA, such as HER2, EGFR, RAS, TP53, and epigenetic alterations detected by cfMeDIP-Seq, such as hMLH, CDH1, CDKN2A, H3K27, are sensitive target of tumorigenesis, which can be detected when clinical symptoms and imaging test are negative. Hence, a ctDNA assay containing the most frequent genomic aberrations and methylation sites is able to detect early-stage GC in time.

Moreover, liquid biopsy is expected to play a significant role in guiding treatment for GC in three aspects, treatment selection, treatment monitoring, and treatment resistance, as it is in other cancers. First, genetic aberrations that are targeted by certain drugs can be detected by ctDNA. For example, detected by Cobas EGFR mutation test v2, a digital PCR assay approved by FDA, non-small-cell lung cancer patients with EGFR exon 19 deletion or exon 21 L858R mutation can be treated by EGFR tyrosine kinase inhibitor erlotinib. Besides, PI3Kα inhibitor alpelisib is suitable for breast cancer patients with PIK3CA mutations detected by the PIK3CA RQG PCR kit. It is reasonable to foresee commercial assays detecting GC-related genetic mutations, HER2, EGFR, KRAS, etc., being used to help doctors treat patients. Treatment efficiency can be monitored by CTCs and ctDNA after primary treatment, as they represent the tumor burden and minimal residual disease. Once the efficiency of treatment dropped unexpectedly, patients are likely resistant to present treatment. ctDNA could not only detect known resistance mechanisms, such as co-mutations and CNAs, but also unknown resistance mechanisms by large gene panels. Alternative treatments can be tested by CTCs isolated from patients with developing resistance. According to previous research, long-term expansion cells, xenografts, spheroids, and organoids are prepared to overcome drug resistance by mimicking patients’ tumor microenvironment step by step.

With respect to the prognosis for GC, CTCs with specific surface markers deserve further exploration. CTCs detection before treatment can be used as baseline data to stratify patients into different groups. With serial blood testing after primary treatment, the possibility of cancer relapse and metastasis could be predicted.

Although the exploration of liquid biopsy is advancing, the challenges of applying liquid biopsy should not be underestimated. The number of CTCs and ctDNAs is low and their distribution is uneven in peripheral circulation, which greatly limits
the reproducibility of liquid biopsy. Besides, the standardization of liquid biopsy needs to be improved, due to the complex procedures, for instance, sample collection, target separation and detection, and lack of reference materials. Additionally, multicentre, larger, and longer-term clinical trials, are urgently required for the clinical use of liquid biopsies.

CONCLUSION
In recent years, liquid biopsy has received extensive attention from clinicians. In this article, the components of liquid biopsy and the role they played in GC are discussed in greater detail. With liquid biopsy, early diagnosis, prognosis prediction, and treatment guidance for GC will become easier in the near future, providing new opportunities for management, and even overcoming the GC.

Fig. 4 Overview of characteristics and clinical applications of liquid biopsy in gastric cancer. Liquid biopsy is regarded as an important tool in the future, as it could achieve multiple goals, such as early detection, medication guidance, treatment monitoring, resistance testing, minimal residual disease (MRD) detection, survival analysis and metastatic prediction. CTCs and ctDNA/cfDNA are primary targets of liquid biopsy, while other targets are being explored, for example, exosomes containing proteins or DNA and RNA fragments, tumor-educated platelets and circulating tumor proteins. Methods like mutation profiling, CNA profiling, methylation profiling and preferred end coordinates detections are used to acquire qualitative and quantitative information of ctDNA. Assays for single locus and multiple target gene panel are being developed. CTCs provide DNA, RNA protein expression and molecular phenotype at single cell level and can be cultured in vivo or in vitro for further investigation.

REFERENCES
1. Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264–79.
3. Tan MC, Graham DY. Screening for gastric cancer: focus on the ants instead of the ant hill. Clin Gastroenterol Hepatol. 2021;19:1990–1.
4. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–v49.
5. Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, et al. Gastric cancer: translating novels concepts into clinical practice. Cancer Treat Rev. 2019;79:101889.
6. Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:114.
27. Miki Y, Yashiro M, Kuroda K, Okuno T, Togano S, Masuda G, et al. Circulating 25. Chen Y, Yuan J, Li Y, Li X, Yang Y, Li J, et al. Prog–
26. Ishiguro Y, Sakihama H, Yoshida T, Ichikawa N, Homma S, Fukai M, et al. Prog-
20. Huang X, Gao P, Sun J, Chen X, Song Y, Zhao J, et al. Clinicopathological and 
18. Watanabe T, Okumura T, Hirano K, Yamaguchi T, Sekine S, Nagata T, et al. Cir–
17. Kang HM, Kim GH, Jeon HK, Kim DH, Jeon TY, Park DY, et al. Circulating tumor 
13. Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, Ilyas A, et al. Circulating tumor 
21. Carneiro A, Piairo P, Teixeira A, Ferreira D, Cotton S, Rodrigues C, et al. Dis–
10. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 
8. Nagasaka M, Uddin MH, Vassouklin V, Lyayute J, Lederrey C, Lefort F, et al. The 
51. Zhong Y, Fan Q, Zhou Z, Wang Y, He K, Lu J. Plasma cfDNA as a potential 
54. Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, et al. Circulating methylated XAF1 
53. Ren J, Lu P, Zhou X, Liao Y, Liu X, Li J, et al. Genome-scale methylation analysis of 
52. Kandimalla R, Xu J, Link A, Matsuyama T, Yamamura K, Parker MI, et al. EpiPanGI 
36. Li TT, Liu H, Li FP, Hu YF, Mou TY, Lin T, et al. Evaluation of epithelial–mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response. World J Gastroenterol. 2015;21:13259–67. 
2015;33:129–31. 
7. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The 
43. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The 
42. –
39. Matsushita D, Uddin MH, Al-Hallak MN, Rahman S, Balasubramanian S, Sukari A, et al. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell. 2020;37:485–95. 
35. Lee SJ, Lee J, Kim ST, Park JO, Park YS, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Markers. 2015;30:e382–24. 
24. –
23. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;82:98–102. 
22. –
21. –
20. –
19. –
18. –
17. –
16. –
15. –
14. –
13. –
12. –
11. –
10. –
9. –
8. –
7. –
6. –
5. –
4. –
3. –
2. –
1. –
56. Hideura E, Suehio Y, Ishikawa J, Shuto T, Fujimura H, Ito S, et al. Blood-free circulating DNA testing of methylated RUNX3 is useful for diagnosing early gastric cancer. Cancers. 2020;12:789–801.
57. Alarcón MA, Olivasares W, Córdova-Delgado M, Muñoz-Medel M, de Mayo T, Carrasco-Añoñô N, et al. The Reprimo-like gene is an epigenetic-mediated tumor suppressor and a candidate biomarker for the non-invasive detection of gastric cancer. Int J Mol Sci. 2020;21:9472–87.
58. Yan H, Chen W, Ge K, Mao X, Li X, Liu W, et al. Value of plasma methylated SFRP2 in prognosis of gastric cancer. Dig Dis Sci. 2021;66:3854–61.
59. Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, et al. Prognostic role of APC and RASSF1A promoter methylation status in cell free DNA of operable gastric cancer patients. Mutat Res. 2015;778:66–71.
60. Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripisianis G, Tentes AA, et al. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin Chem Lab Med. 2013;51:1505–10.
61. Han J, Lv P, Yu J, Wu YC, Zhu X, Hong LL, et al. Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer. Dig Dis Sci. 2014;59:1160–8.
62. Hu XY, Ling ZN, Hong LL, Yu QM, Li P, Ling ZQ. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer. J Clin Lab Anal. 2021;35:e23936.
63. Wan JCM, Massie C, Garcia-Corbacho J, Moullere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.
64. Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 2020;11:346.
65. Ko K, Kananazawa Y, Yamada T, Kakinuma D, Matsuno K, Ando F, et al. Longitudinal monitoring of circulating tumour DNA improves prognostic and relapse detection in gastroesophageal adenocarcinoma. Br Cancer J. 2020;123:1271–91.
66. Varkalaite G, Forster M, Franke A, Kupcinskas J, Skieceviciene J. Liquid biopsy in gastric cancer. Cancers. 2020;12:789.
67. Maron SB, Joshi SS, Lomnicki S, Oliwa T, Landron S, Johnson J, et al. Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in circulating tumor DNA analysis predict disease progression in patients with non-small cell lung cancer. J Immunother Cancer. 2020;8:e000110.
68. Xie Y, Deng W, Zhang S, Yue W, Yang L, Zhai X, et al. The role of exosomal noncoding RNAs in cancer. Mol Cell. 2019;18:37.
69. Maron SB, Joshi SS, Lomnicki S, Oliwa T, Landron S, Johnson J, et al. Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis. Ann Surg Oncol. 2019;26:3745–51.
70. Fan Y, Che X, Xu J, Hou K, Wen T, Li Z, et al. Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis. Ann Surg Oncol. 2021;28:7399–40.
71. Calverley DC, Phang TL, Choudhury QQ, Gao B, Oton AB, Weyant MJ, et al. Significant downregulation of platelet gene expression in metastatic lung cancer. Cell Transl Sci. 2010;3:227–32.
72. Nilsson RJ, Balaj L, Hullemen E, van Rijn S, Pegtel DM, Walraven M, et al. Blood cell-free circulating DNA markers correlate with tumor-derived exosomal RNA biomarkers. Nat Commun. 2021;12:3860–3.
73. Nilsson RJ, Balaj L, Hullemen E, van Rijn S, Pegtel DM, Walraven M, et al. Blood cell-free circulating DNA markers correlate with tumor-derived exosomal RNA biomarkers. Nat Commun. 2021;12:3860–3.
74. Nilsson RJ, Balaj L, Hullemen E, van Rijn S, Pegtel DM, Walraven M, et al. Blood cell-free circulating DNA markers correlate with tumor-derived exosomal RNA biomarkers. Nat Commun. 2021;12:3860–3.
75. Hoshino I. The usefulness of microRNA in urine and saliva as a biomarker of gastroesophageal adenocarcinoma (GEJ). J Clin Oncol. 2018;36:45–5.
76. Openshaw MR, Mohamed AA, Oottolini B, Fernandez-Garcia D, Richards CJ, Page MJ, et al. Longitudinal monitoring of circulating tumour DNA improves prognostic and relapse detection in gastroesophageal adenocarcinoma. Br Cancer J. 2020;123:1271–91.
77. Varkalaite G, Forster M, Franke A, Kupcinskas J, Skieceviciene J. Liquid biopsy in gastric cancer: analysis of somatic tumor tissue mutations in plasma cell-free DNA for predicting disease state and patient survival. Clin Transl Gastroenterol. 2021;12:e00403.
78. Maron SB, Joshi SS, Lomnicki S, Oliwa T, Landron S, Johnson J, et al. Circulating tumor dna (ctdna) landscape and prognostic implications in advanced gastroesophageal adenocarcinoma (GEJ). J Clin Oncol. 2018;36:45–5.
79. Li J, Li Z, Ding Y, Xu Y, Zhu X, Cao N, et al. TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer. PeerJ. 2021;9:e11146.
80. Karamitrousis EJ, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Prognostic role of RASSF1A, SOX17 and Wnt-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients. Technol Cancer Res Treat. 2020;19:333–42.
81. Yu JL, Lv P, Han J, Zhu X, Hong LL, Zhu WY, et al. Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer. Arch Pathol Lab Med. 2014;138:1466–73.
82. Li J, Jiang W, Wei J, Zhang J, Cai L, Luo M, et al. Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors. J Transl Med. 2020;18:293.
83. Kim ST, Cristescu R, Bass AJ, Kim KM, Odegard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449–58.
84. Shin HM, Kim G, Kim S, Sim JH, Choi J, Kim M, et al. Chromatin accessibility of circulating CD8(+)+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. Nat Comm. 2021;12:973.
85. Chen Z, Zhang C, Zhang M, Li B, Niu Y, Chen L, et al. Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. Cell Death Dis. 2019;10:697.
86. Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020;19:154.
87. Kwon EL, Ahn R, Gronia D, Srinvasa G, Musolino B, Borger DR, Godfrey JT, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagealgastric cancer. Cancer Discov. 2015;5:1271–81.
88. Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lannan RB, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018;29:1037–48.
89. Wang H, Fu M, Liu J, Chong W, Fang Z, Du F, et al. The role and application of small extracellular vesicles in gastric cancer. Mol Cancer. 2021;20:71.
90. Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487–514.
91. Iwasaki H, Shimura T, Yamada T, Okuda Y, Natsune M, Kitagawa M, et al. Novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol. 2019;54:1061–9.
92. Kuo HW, Pan CY, Lai CH, Wu CW, Fang WL, Huang KH, et al. Urinary miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget. 2017;8:56389–97.
93. Hsu L, Liu J, Shimada H, Ito M, Sugimoto K, Hiwasa T, et al. Serum Anti-BRAT1 is a useful serum marker for gastric cancer. Int J Mol Sci. 2020;21:7906.

ACKNOWLEDGMENTS
The authors apologize to the investigators and research laboratories whose original studies were not cited because of space limitations. Figures were created with BioRender.com and VOSviewer.
AUTHOR CONTRIBUTIONS
All authors helped to perform the research; ZZ and HW were involved in the conception and design; ZZ and LS were involved in the drafting of the paper or revising it critically for intellectual content; CJ and LL were involved in the final approval of the version to be published. All authors agreed to be accountable for all aspects of the work.

FUNDING
Supported by Key Research and Development Program of Shandong Province (No. 2019JZZY010104; No. 2019GSF108146; No. 2021SGC0502; No. 2021CXGC011104); Special Foundation for Taishan Scholars Program of Shandong Province (No. ts20190978); Academic promotion program of Shandong First Medical University (No. 2019QL021).

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Liang Shang, Changqing Jing or Leping Li.